出处
《山东医药》
CAS
北大核心
2006年第7期79-80,共2页
Shandong Medical Journal
基金
湖北省教育厅青年基金项目(Q2005B002)
参考文献9
-
1Kneissel M,Boyed A,et al.Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone analog SDZPTS893or human PTH(1-34)[J].Bone,2001,28:237-250.
-
2Seebach C,Skripitz P,Andreassen TT,et al.Imtemittent parathyroid hormone(1-34)enhance mechanical strength and density of new bone after distraction osteogenesis in rats[J].Orthop Res,2004,22(3):472-478.
-
3王洪复,金慰芳,高建军,顾淑珠,周轶,孙爱龙,胡菲,沈洁,张顺昌.重组人甲状旁腺激素_(1-34)对去卵巢大鼠骨质疏松的治疗作用[J].中国医学科学院学报,2003,25(3):275-279. 被引量:25
-
4金慰芳,王洪复,顾淑珠,周轶,高建军,徐培康,徐爱红,王漪,周永春.rhPTH_(1-34)治疗糖皮质激素诱发大鼠骨质疏松症的实验研究[J].中国骨质疏松杂志,2004,10(4):461-465. 被引量:6
-
5Nakazawa T,Nakajima A,Shiomi K,et al.Effects of low-dose,intermittent treatment with recombinant human parathyroid hormone(1-34) on chondrdgenesis in a model of experimental fracture healing[J].Bone,2005,37(5):711-719.
-
6Neer RM,Arnaud CD,Zanchetta JR,et al.Effect of parathyroid hormone(1-34) on fractures and bone mineral densith in postmenopausal women with osteoporosis[J].N Engl J Med,2001,344(19):1434-1441.
-
7Orwoll ES,Scheele WH,Paul S,et al.The effect of teripratide[human parathyroid hormone(1-34)]therapy on bone density in men with osteoporosis[J].J Bone Mineral Research,2003,18(1):9-17.
-
8Cosmen F,Nieves J,Zion M,et al.Parathyroid hormone in women receiving alendronate[J].N Engl J Med,2005,353(6):566-75.
-
9Miao D,He B,Andrew CK,et al.Parathyroid hormone is essential for normal fetal bone formation[J].Clin Imvest,2002,109(9):1173.
二级参考文献22
-
1[1]Shen V, Dempster DW, Mellish RW, et al. Effects of combined and separate intermitten administration of low-dose human parathyroid hormone fragment(1-34) and 17 β-estradiol on bone histomrphometry inovari-ectomied rats with established osteopenia. Calcif Tissue Int, 1992, 50:214-220.
-
2[2]Baumann BD, Wronski TJ. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone, 1995,16: 247-253.
-
3[3]Ejersted C, Andreassen TT, hauge EM. Parathyoid hormone(1-34) increasesvertebral bone mass, compressive strength, and quality in old rats.Bone, 1995, 17:507-551.
-
4[4]Dempaser DW, Cosman F, Parisien M, et al. Anabolic actins of parathyroid hormone on bone. Endocrine Rev, 1993,14:690-709.
-
5[5]Miller SC, Hunziker J, Mecham M, et al. Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged overiectomiged rats. J Dent Res, 1997,76:1471-1476.
-
6[6]Ejersted C, Andeassen TT, Hauge EM, et al. Parathyroid hormone(1-34) in creases vertebral bone mass, compressive strength, and quality in old rats. Bone, 1995,17:507-511.
-
7[7]Hunziker J, Wronski TJ, Miller SC. Mandibular bone formation rates in aged ovariectomized rats treated with anfi-resorptive agents alone and in combination with intermittent parathyriod hormone. J Dent Res, 2000,79:1431-1438.
-
8[8]Brommage R, Hotchkiss CE, Less C J, et al. Daily treatment with human recombinant parathyoid hormone(1-34), LY333334, for 1 year increases bone mass inovariectomiged monkeys. J Clin Endocrinol Metab, 1999,84: 3757-3763.
-
9[9]Robert L, Carmelo F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal woman on osetrogen with osteoporosis. LANCET, 1997,350:550-555.
-
10[10]Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with huamn parathyroid hormone(1-34) . JAMA, 1998,280:1067-1073.
共引文献26
-
1董芒艳,董进.骨质疏松症的非性激素药物治疗新进展[J].基层医学论坛,2008,12(28):943-944. 被引量:1
-
2阮峰,肖德明.PTH治疗骨质疏松症的研究进展[J].中国骨肿瘤骨病,2004,3(5):268-272. 被引量:4
-
3张颖,彭永德.骨质疏松症治疗新药特立帕肽[J].世界临床药物,2004,25(12):725-729. 被引量:8
-
4丰盛梅,高建军,金慰芳.PTH作用于老年大鼠骨髓细胞骨代谢相关基因表达的实验方法[J].复旦学报(医学版),2005,32(2):219-221. 被引量:6
-
5金慰芳,王洪复,高建军,徐培康,徐爱红,骆宏丰,胡昌奇.锦鸡儿有效成分对卵巢摘除大鼠骨质疏松的防治作用[J].复旦学报(医学版),2005,32(3):305-308. 被引量:4
-
6文力,王革非,冷武军,王贞慧,杨光.人甲状旁腺素N-端34肽基因的合成、克隆和融合表达[J].中国生物制品学杂志,2005,18(4):284-287.
-
7于志锋,金慰芳,顾淑珠,高建军,周轶,王洪复.rhPTH_((1-34))治疗OVX大鼠骨质疏松延后效应的初步研究[J].中国骨质疏松杂志,2005,11(3):278-280. 被引量:3
-
8金慰芳,于志锋,高建军,顾淑珠,周轶,王洪复.PTH对骨髓细胞骨代谢相关基因表达的影响[J].中国骨质疏松杂志,2005,11(3):286-288. 被引量:11
-
9彭永德,张颖.甲状旁腺素类似物在骨质疏松症治疗中的应用[J].中国临床保健杂志,2006,9(1):85-87. 被引量:2
-
10廖建民,张奉国,常高翔,沈子龙.^(125)I示踪法研究rhPTH_(1~34)在大鼠体内的药代动力学[J].同位素,2006,19(4):223-227. 被引量:3
同被引文献29
-
1彭绩,梁渊,卢祖洵.骨质疏松症危险因素的Meta分析[J].中国公共卫生,2004,20(5):585-586. 被引量:37
-
2袁志栋,王志亮,刘雨田,吴晓东,刘海生.水貂朊蛋白前体基因的原核表达[J].云南大学学报(自然科学版),2005,27(2):180-184. 被引量:2
-
3刘剑刚,谢雁鸣,徐哲,赵晋宁,邓文龙.骨碎补总黄酮的活血化瘀作用及对实验性微循环障碍和骨质疏松症的影响[J].中国骨质疏松杂志,2006,12(1):46-49. 被引量:56
-
4蒋利华.骨质疏松症药物治疗进展[J].中国药业,2006,15(4):3-5. 被引量:4
-
5张凯,王毅,王学谦.重组甲状旁腺激素与骨质疏松关系的研究新进展[J].中国骨伤,2006,19(6):383-384. 被引量:4
-
6刘新宇,梁东春,左爱军,张镜宇,郭刚.重组人甲状旁腺激素相关蛋白1-141的表达和生物活性测定[J].天津医药,2007,35(1):33-36. 被引量:1
-
7刘忠厚.钙剂的基础研究及临床应用[J].中国骨质疏松杂志,1996,8:70-70.
-
8NIH consensus statement. Osteoporosis Prevention, Diagnosis, Therapy[ EB/OL]. 2000, 17 ( 1 ) : 1-45.
-
9QIN Ling,RAGGATT Liza J, PARTRIDGE Nicola C, et al. Parathyroid hormone: a double-edged sword for bone metabolism [ J]. TRENDS in Endocrinology and Metabolism, 2004, 15 (2) : 60-65.
-
10DIVIETI P, INOMATA N, CHAPIN K, et al. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteoeytie cells[J]. Endocrinology, 142(2) :916-925.
引证文献4
-
1刘丰亮,常宏,刘洁,杨克,张杰.重组人甲状旁腺素(rhPTH(1-84))的原核表达及发酵条件初步优化[J].云南大学学报(自然科学版),2008,30(2):198-201. 被引量:1
-
2卢杭桢,吴伏娜,钟紫茹,李岚.男性慢性阻塞性肺病患者骨密度对照分析[J].中国骨质疏松杂志,2008,14(7):515-516. 被引量:5
-
3邓华,初晓辉,殷红,陈小波,徐志强,谷大海,樊月圆,葛长荣,贾俊静,廖国周,荣华.甲状旁腺激素对骨代谢相关基因调控的研究进展[J].中国畜牧兽医,2013,40(3):141-145. 被引量:3
-
4袁翔城,梁宇娴,宋严,俞晓磊,黄晖,周伟华.CO_(2)升高对风信子鹿角珊瑚(Acropora hyacinthus)钙化速率和 基因表达的影响[J].热带海洋学报,2024,43(3):40-48.
二级引证文献9
-
1胡美,王萍,彭文鸿,王瑞娟,霍苗,许杨,李考,李小娜,聂巧红.老年慢性阻塞性肺疾病患者发生骨质疏松的危险因素[J].中华老年医学杂志,2009,28(9):708-711. 被引量:10
-
2陈尚德,龚美龙,马继利.老年慢性阻塞性肺疾病(COPD)患者腰椎、股骨骨密度和尿DPD测定分析[J].西北国防医学杂志,2009,30(6):449-450.
-
3周俊荣.沙美特罗替卡松气雾剂联合噻托溴铵对重度-极重度COPD患者肺功能和生活质量的改善作用[J].中国老年学杂志,2010,30(15):2212-2213. 被引量:14
-
4陈耀国.乳糖诱导表达重组人甲状旁腺激素rhPTH(1-34)[J].齐鲁药事,2012,31(2):63-65.
-
5皇甫秋强,陶鸿杰,王玮,肖丽娜.短期吸入沙美特罗氟替卡松对慢性阻塞性肺疾病老年男性患者骨密度的影响[J].中华老年医学杂志,2013,32(8):880-881. 被引量:6
-
6刘佳,高艳虹.甲状旁腺素相关肽治疗绝经后骨质疏松症的研究进展[J].中国骨质疏松杂志,2018,24(11):1521-1525. 被引量:6
-
7申黎艳,林存智,张少燕,徐丽丽,王飞,王青.血清总Ⅰ型氨基末端延长肽和维生素D3对慢性阻塞性肺疾病患者罹患骨质疏松诊断价值分析[J].中国医师进修杂志,2015,38(12):894-897.
-
8李永頔,唐正龙.大鼠成骨细胞增殖及护骨素蛋白含量与甲状旁腺激素的调节效应[J].现代诊断与治疗,2016,27(16):2948-2950. 被引量:1
-
9韩立华,王菲,戴宇峰,姜晓明,王静凤.南极磷虾肽对去卵巢骨质疏松症小鼠肠钙吸收的改善作用研究[J].中国海洋药物,2017,36(5):42-48. 被引量:4
-
1阮峰,肖德明.PTH治疗骨质疏松症的研究进展[J].中国骨肿瘤骨病,2004,3(5):268-272. 被引量:4
-
2鲍舟君,安明和,姚燕珍,张朝峰.甲状腺手术对甲状旁腺分泌功能的影响[J].放射免疫学杂志,2010,23(3):357-358.
-
3韦光海.急性颅脑损伤患者血液流变学、血糖水平动态变化及其意义[J].国际检验医学杂志,2009,30(1):84-85. 被引量:3
-
4Chobanian MC,王继英.肾脏氨代谢的激素调节[J].国外医学(内分泌学分册),1990,10(4):188-189.
-
5凌建煜,祝宇,孙福康.围肾移植期甲状旁腺功能和钙、磷代谢的改变[J].中华器官移植杂志,1999,20(2):128-128.
-
6熊咏民,吕社民,樊唯真,张矢远,白思.硒对大骨节病区儿童肾脏磷代谢的影响[J].地方病通报,1992,7(2):69-72.
-
7董浩,刘巍,刘凤岐.甲状旁腺激素在心力衰竭中的作用[J].国际心血管病杂志,2015,42(1):36-37. 被引量:2
-
8石敏,周莉,付平.慢性肾脏病高磷血症肾损伤机制的研究进展[J].中国中西医结合肾病杂志,2016,17(1):76-78. 被引量:7
-
9程书权.关于维生素D 哪些事您还不了解[J].肝博士,2017,0(2):34-36.
-
10侯淑琴,陈琳.生长抑素治疗急性中、重型胰腺炎——附7例报告[J].现代消化病及内镜杂志,1997,2(2):155-156.